Contact
searchSearch
HMP Global
CIO2022 Highlights

Edward Kim, MD, FSIR, Discusses the Updated Clinical and Dosimetric Recommendations for Y-90 Glass Microspheres in HCC

Edward Kim, MD
10/26/2022

Introduction

Dr Edward Kim discusses his CIO2022 abstract, "Updated Clinical and Dosimetric Recommendations for Yttrium-90 Glass Microspheres in Hepatocellular Carcinoma." 

CLICK HERE TO READ THE FULL ABSTRACT AND VIEW POSTER

Video


Related Content

FIgure 2B
Case Study
Embolization of Primary and Metastatic Hepatic Tumors Using the Embrace™ Hydrogel Embolic System: Case Studies
09/26/2025
Edgar St. Amour, MD; Nadine Abi-Jaoudeh, MD
These cases were part of the Instylla HES Hypervascular Tumor Pivotal Study to evaluate the safety and effectiveness of Embrace HES compared with standard of care TAE or TACE.
These cases were part of the Instylla HES Hypervascular Tumor Pivotal Study to evaluate the safety and effectiveness of Embrace HES compared with standard of care TAE or TACE.
These cases were part of the...
09/26/2025
Vascular Disease Management
TheraSphere webinar image
Webinar
Evidence to Impact: Treating Large HCC Tumors with TheraSphere™ Y-90 Glass Microspheres
09/17/2025
Join Dr. Tyler Sandow for an expert-led discussion on how TheraSphere™ Y-90 is redefining treatment for large hepatocellular carcinoma (HCC) tumors. This session will highlight the latest clinical data, explore the importance of radiation per...
Join Dr. Tyler Sandow for an expert-led discussion on how TheraSphere™ Y-90 is redefining treatment for large hepatocellular carcinoma (HCC) tumors. This session will highlight the latest clinical data, explore the importance of radiation per...
Join Dr. Tyler Sandow for an...
09/17/2025
Vascular Disease Management
Nadine Abi-Jaoudeh, MD, University of California, Irvine
Videos
Oncology Drugs With an Impact on IR Procedures
10/16/2024
Nadine Abi-Jaoudeh, MD
Nadine Abi-Jaoudeh, MD, discusses the drugs that interventional radiologists should be on the lookout for when treating patients with cancer.
Nadine Abi-Jaoudeh, MD, discusses the drugs that interventional radiologists should be on the lookout for when treating patients with cancer.
Nadine Abi-Jaoudeh, MD,...
10/16/2024
Vascular Disease Management
Conference Coverage
Lenvatinib Plus Pembrolizumab Added to TACE Significantly Improves PFS in Intermediate-Stage Hepatocellular Carcinoma: LEAP-012
09/14/2024
Janelle Bradley
The LEAP-012 trial met its primary end point demonstrating a statistically significant and clinically meaningful improvement in PFS with the addition of lenvatinib plus pembrolizumab to TACE for patients with intermediate-stage hepatocellular...
The LEAP-012 trial met its primary end point demonstrating a statistically significant and clinically meaningful improvement in PFS with the addition of lenvatinib plus pembrolizumab to TACE for patients with intermediate-stage hepatocellular...
The LEAP-012 trial met its...
09/14/2024
Vascular Disease Management

Stay in the Know

Vascular Disease Management Newsletter

News

Rob Williamson, RAMPART CRO
Industry Leaders
RAMPART Appoints Rob Williamson as Chief Revenue Officer
02/12/2026
As Chief Revenue Officer, Rob Williamson will lead Rampart’s U.S. Sales organization, focusing on revenue growth, field execution, and team expansion.
As Chief Revenue Officer, Rob Williamson will lead Rampart’s U.S. Sales organization, focusing on revenue growth, field execution, and team expansion.
As Chief Revenue Officer, Rob...
02/12/2026
Cath Lab Digest
Radiation Safety
RAMPART Appoints Rob Williamson as Chief Revenue Officer
02/12/2026
BIRMINGHAM, Ala. — February 12, 2026 — Rampart, a Birmingham, Alabama–based medical device company redefining interventional radiation safety, today announced that Rob Williamson has been appointed Chief Revenue Officer (CRO), efective March...
BIRMINGHAM, Ala. — February 12, 2026 — Rampart, a Birmingham, Alabama–based medical device company redefining interventional radiation safety, today announced that Rob Williamson has been appointed Chief Revenue Officer (CRO), efective March...
BIRMINGHAM, Ala. — February 12,...
02/12/2026
Vascular Disease Management
The Salus and Tallahassee Memorial HealthCare teams celebrate after the first AeroShield case.
Radiation Protection Systems
Tallahassee Memorial HealthCare Advances Cath Lab Safety Through First-in-the-World Technology Adoption
02/10/2026
Salus Scientific and Tallahassee Memorial HealthCare (TMH) announced the successful implementation and first clinical use of AeroShield™, a groundbreaking radiation protection technology developed by Salus Scientific.
Salus Scientific and Tallahassee Memorial HealthCare (TMH) announced the successful implementation and first clinical use of AeroShield™, a groundbreaking radiation protection technology developed by Salus Scientific.
Salus Scientific and Tallahassee...
02/10/2026
Cath Lab Digest
Embolic Device
Fluidx Embolic IDE Trial Results Accepted for Late-Breaking Presentation at the SIR Annual Meeting
02/10/2026
Fluidx Medical Technology, Inc. is a clinical-stage medical device company advancing its next-generation gel embolic technology.
Fluidx Medical Technology, Inc. is a clinical-stage medical device company advancing its next-generation gel embolic technology.
Fluidx Medical Technology, Inc....
02/10/2026
Vascular Disease Management
Thrombectomy
Avantec Vascular, a NIPRO Company, Announces FDA 510(k) Clearance of Thrombectomy System
02/10/2026
Sunnyvale, California – Avantec Vascular, a NIPRO Company, has received FDA 510(k) clearance for a thrombectomy system that will enable a new type of treatment for patients with thrombus in the peripheral venous...
Sunnyvale, California – Avantec Vascular, a NIPRO Company, has received FDA 510(k) clearance for a thrombectomy system that will enable a new type of treatment for patients with thrombus in the peripheral venous...
Sunnyvale, California...
02/10/2026
Cath Lab Digest
News
RAMPART Appoints Former Thoratec CEO Gary Burbach as Chairman of the Board
02/04/2026
BIRMINGHAM, Ala. — February 4, 2026 — Rampart, a Birmingham, Alabama–based medical device company redefining interventional radiation safety, today announced the appointment of Gerhard (Gary) F. Burbach as Chairman of its Board of...
BIRMINGHAM, Ala. — February 4, 2026 — Rampart, a Birmingham, Alabama–based medical device company redefining interventional radiation safety, today announced the appointment of Gerhard (Gary) F. Burbach as Chairman of its Board of...
BIRMINGHAM, Ala. — February 4,...
02/04/2026
Vascular Disease Management
Cardiovascular Scientific Forum
AngioDynamics to Convene Cardiovascular Leaders at Scientific Forum as Pipeline Continues to Advance
02/03/2026
Physician-led Collaboration Reinforces Ongoing Regulatory Activity and Clinical Advancement Across the Cardiovascular Portfolio LATHAM, N.Y.--Feb. 3, 2026-- AngioDynamics, Inc. (NASDAQ: ANGO), a medical technology company focused on...
Physician-led Collaboration Reinforces Ongoing Regulatory Activity and Clinical Advancement Across the Cardiovascular Portfolio LATHAM, N.Y.--Feb. 3, 2026-- AngioDynamics, Inc. (NASDAQ: ANGO), a medical technology company focused on...
Physician-led Collaboration...
02/03/2026
Vascular Disease Management
thrombectomy
Penumbra Launches Lightning Flash 3.0 — The Next Evolution in CAVT Technology
01/27/2026
Penumbra recently launched the Lightning Flash® 3.0 Computer Assisted Vacuum Thrombectomy (CAVT™) system, which includes significant upgrades that further advance our leading venous thromboembolism (VTE) platform.
Penumbra recently launched the Lightning Flash® 3.0 Computer Assisted Vacuum Thrombectomy (CAVT™) system, which includes significant upgrades that further advance our leading venous thromboembolism (VTE) platform.
Penumbra recently launched the...
01/27/2026
Cath Lab Digest
Acquisitions
Boston Scientific Announces Agreement to Acquire Penumbra, Inc.
01/15/2026
MARLBOROUGH, Mass. and ALAMEDA, Calif. -- Boston Scientific Corporation and Penumbra, Inc., today announced the companies have entered into a definitive agreement under which Boston Scientific will acquire Penumbra in a cash and stock...
MARLBOROUGH, Mass. and ALAMEDA, Calif. -- Boston Scientific Corporation and Penumbra, Inc., today announced the companies have entered into a definitive agreement under which Boston Scientific will acquire Penumbra in a cash and stock...
MARLBOROUGH, Mass. and ALAMEDA,...
01/15/2026
Cath Lab Digest
Peripheral Arterial Disease
CIS and Terrebonne General Are First in Louisiana to Use the AngioSafe Santreva™-ATK Endovascular Revascularization Catheter
01/09/2026
JANUARY 8, 2026 –HOUMA, LA – Cardiovascular Institute of the South (CIS) and Terrebonne General Health System (Terrebonne General) are the first in Louisiana to use the AngioSafe Santreva™-ATK Endovascular Revascularization Catheter to...
JANUARY 8, 2026 –HOUMA, LA – Cardiovascular Institute of the South (CIS) and Terrebonne General Health System (Terrebonne General) are the first in Louisiana to use the AngioSafe Santreva™-ATK Endovascular Revascularization Catheter to...
JANUARY 8, 2026 –HOUMA, LA...
01/09/2026
Vascular Disease Management

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use